| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 3192883 | Annals of Allergy, Asthma & Immunology | 2008 | 9 Pages |
Abstract
Additional SCIT was associated with improved medical outcomes and cost savings compared with symptomatic treatment alone according to a societal perspective. Taking a European accepted ICER threshold of up to â¬50,000 per QALY into account, additional SCIT is considered clearly cost-effective compared with routine care in Germany. The degree of cost-effectiveness is strongly affected by costs related to SCIT and the target population receiving such treatment.
Related Topics
Health Sciences
Medicine and Dentistry
Dermatology
Authors
Bernd MD, Thomas MSc, Randolf MD, Eckard MD, Günther MD, Ulrich MD, Stefan N. MD, MPH,